Use of MHT in women with cardiovascular disease: a systematic review and meta-analysis

S. Bontempo, L. Yeganeh, R. Giri, A. J. Vincent

Research output: Contribution to journalReview ArticleResearchpeer-review

3 Citations (Scopus)

Abstract

This systematic review assesses the effect of menopausal hormone therapy (MHT) on cardiovascular outcomes and risk factors in postmenopausal women with cardiovascular disease (CVD). The Medline, Embase and Cochrane databases were searched from inception to December 2022 for randomized controlled trials (RCTs) and observational studies using methodology from a previous Cochrane review. Quality assessment used the Cochrane risk of bias tool and Newcastle–Ottawa scale, respectively. From 5647 studies identified, 29 (23 RCTs and six observational studies) were included. Most studies were conducted in North America or Europe and investigated oral estrogens. Participants were older with varying frequency of cardiac risk factors and underlying CVD. No significant difference was observed between MHT users and controls regarding primary outcomes of non-fatal myocardial infarction, cardiovascular death or stroke. No difference in frequency of angina, heart failure and transient ischemic attacks was observed. Inconsistent effects of MHT on angiographic progression were seen and varied with glycemic status. Estradiol had a positive effect on flow-mediated dilatation. Limited studies identified differing effects of MHT on cardiac risk factors, varying with estrogen preparation. This study confirms no benefit of MHT for secondary CVD prevention, highlighting evidence limitations and the importance of shared decision-making when managing menopausal symptoms in women with CVD.

Original languageEnglish
Pages (from-to)93-103
Number of pages11
JournalClimacteric
Volume27
Issue number1
DOIs
Publication statusPublished - 2024

Keywords

  • cardiovascular disease
  • heart
  • Menopausal hormone therapy
  • menopause
  • systematic review

Cite this